University of North Carolina at Chapel Hill (Site 1001), 130 Mason Farm Rd., Bioinformatics Bldg, 2nd Floor
Welcome,         Profile    Billing    Logout  
 0 Trials 
7 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Straub, Becky
NCT04636437: Doravirine for Persons With Excessive Weight Gain on Integrase Inhibitors and Tenofovir Alafenamide

Active, not recruiting
4
222
US
Doravirine 100 Mg, Tenofovir alafenamide/emtricitabine, tenofovir alafenamide/lamivudine, Integrase strand transfer inhibitors, tenofovir disproxil fumarate/emtricitabine, tenofovir disproxil fumarate/lamivudine
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
11/24
11/24
BEe-HIVe, NCT04193189: B-Enhancement of HBV Vaccination in Persons Living With HIV (): Evaluation of HEPLISAV-B

Completed
3
640
US, RoW
HEPLISAV-B, ENGERIX-B
National Institute of Allergy and Infectious Diseases (NIAID), Dynavax Technologies Corporation
HIV Infection, Hepatitis B
08/24
08/24
NCT03635788: The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE

Active, not recruiting
3
310
US
Standard of Care (SOC) Oral ART, Oral RPV, Rilpivirine, Oral CAB, Cabotegravir, GSK1265744, RPV-LA Loading Dose, Rilpivirine Long-Acting Injectable, CAB-LA Loading Dose, Cabotegravir Long-Acting Injectable, RPV-LA Maintenance Dose, CAB-LA Maintenance Dose
National Institute of Allergy and Infectious Diseases (NIAID), ViiV Healthcare
HIV Infections
11/24
08/26
PURGE-C, NCT04042740: Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection

Completed
2
45
US, RoW
Glecaprevir/Pibrentasvir (G/P), Mavyret
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, AbbVie, National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis C Infection, HIV Infection
05/23
08/23
NCT05099965: Trial to Evaluate the Safety and Immunogenicity of a Modified Vaccinia Ankara (MVA)-Based Anti-Cytomegalovirus (CMV) Vaccine (Triplex®)

Active, not recruiting
2
90
US
CMV-MVA Triplex, Placebo
National Institute of Allergy and Infectious Diseases (NIAID)
Cytomegalovirus Infections, HIV Infections, Vaccine
11/24
10/25
NCT03705169: Pharmacokinetics and Safety of SAR441236

Terminated
1
52
US
SAR441236, Placebo
National Institute of Allergy and Infectious Diseases (NIAID), Sanofi, ModeX Therapeutics
HIV-1-infection
04/22
04/22
NCT04340596: Safety, Tolerability, and Efficacy of IL-15 Superagonist (N-803) With and Without Combination Broadly Neutralizing Antibodies to Induce HIV-1 Control During Analytic Treatment Interruption

Recruiting
1
46
US
N-803 (IL-15 Superagonist), VRC07-523LS, 10-1074
National Institute of Allergy and Infectious Diseases (NIAID), Rockefeller University, ImmunityBio, Inc.
HIV Infection
06/26
12/26

Download Options